search
Back to results

Testing the Efficacy of an Eye-tracking-based Treatment in Reducing Stress-related Symptoms in Veterans With PTSD

Primary Purpose

Posttraumatic Stress Disorder

Status
Recruiting
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
Gaze-Contingent Feedback Training
Attention Bias Modification
Non-Contingent Feedback Training
Sponsored by
Tel Aviv University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Posttraumatic Stress Disorder

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of PTSD according to the DSM-5 and related to military service, ages 20-70

Exclusion Criteria:

  • Psychotic or Bipolar disorder, drug and alcohol abuse, high risk of harming self or others, other psychological treatment, vision problems that are not overcome with regular glasses, physical disability that prevents ability to operate computer.

Sites / Locations

  • Tel Aviv UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

Gaze-Contingent Feedback Training

RT-Based Attention Bias Modification

Non-Contingent Feedback Training

Arm Description

In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the veteran will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracking technology, the veteran will be instructed to view the matrices of faces as he chooses, as described above in the assessment task. The music chosen by the veteran will play only when s/he is looking at neutral faces and it will stop when s/he looks at threatening faces.

The task consists of 160 trials. Each trial begins with a centrally-presented fixation cross (+), on which the participant is asked to focus for 500ms. When it disappears, two stimuli will be presented 1.5cm above and below the previous fixation cross for 500ms. After the stimuli disappear, a target probe (right- or left-pointing arrowhead) will appear in place of one of the stimuli, and the participant will be asked to indicate which target probe is presented by pressing the respective key. The target probe will remain on the screen until the participant's response, after which a new trial will begin. Participants are instructed to identify the probe type as quickly and accurately as possible. In the training task, all of the target probes will appear in the neutral face location. Thus, over multiple trials, learning occurs that the threatening face predicts the location of the target probe, thereby achieving the desiring change in attention patterns.

This condition is based on the aforementioned eye-tracking task with a fundamental change - The music chosen by the veteran will play continuously without any reinforcement for looking at threat or neutral faces.

Outcomes

Primary Outcome Measures

Change in Clinician-rated PTSD symptoms from Pre- to Post-Treatment
Change in total score on the Clinician Administered PTSD Scale (CAPS-5) from pre- to post-treatment
Clinician-rated PTSD symptoms at 3-month Follow-up
Total score on the Clinician Administered PTSD Scale (CAPS-5) at 3-month Follow-up
Change in PTSD Diagnosis from Pre- to Post-Treatment
Change in PTSD diagnosis, derived from CAPS-5 corresponding to DSM-5 criteria, from pre- to post-treatment
PTSD Diagnosis at 3-month Follow-up
PTSD diagnosis derived from CAPS-5 corresponding to DSM-5 criteria at 3-month Follow-up

Secondary Outcome Measures

Change in Patient-rated PTSD symptoms from Pre- to Post-Treatment
Change in score on self-report questionnaire Posttraumatic stress disorder checklist for DSM-5 (PCL-5) from Pre- to Post-Treatment. The total score, ranging from 0 to 80, reflects PTSD symptom severity, with higher scores representing greater severity.
Patient-rated PTSD symptoms at 3-month Follow-up
Score on self-report questionnaire Posttraumatic stress disorder checklist for DSM-5 (PCL-5) at 3-month Follow-up. The total score, ranging from 0 to 80, reflects PTSD symptom severity, with higher scores representing greater severity.
Change in Patient-rated Depression symptoms from Pre- to Post-Treatment
Change in Score on self-report Patient Health Questionnaire 9 (PHQ-9) from Pre- to Post-Treatment. The total score, ranging from 0-27, reflects severity of depressive symptoms, with higher scores representing greater severity.
Patient-rated Depression symptoms at 3-month Follow-up
Score on self-report Patient Health Questionnaire 9 (PHQ-9) at 3-month Follow-up. The total score, ranging from 0-27, reflects severity of depressive symptoms, with higher scores representing greater severity.
Pre-treatment Clinical Global Impression Scale
Clinician Rated Symptom Severity & Improvement. Severity and improvement scales (CGI-S/I) will be used to assess participants global clinical condition. The CGI-S and the CGI-I are single-items, clinician-reported, measure assessing severity and improvement of illness using a 7-point Likert-type scale. The CGI-S/I has good inter-rater reliability and concurrent validity with other measures. This tool is widely used in clinical trials concerning psychopathology treatments and has good sensitivity to clinical change.
Post-treatment Clinical Global Impression Scale
Clinician Rated Symptom Severity & Improvement. Severity and improvement scales (CGI-S/I) will be used to assess participants global clinical condition. The CGI-S and the CGI-I are single-items, clinician-reported, measure assessing severity and improvement of illness using a 7-point Likert-type scale. The CGI-S/I has good inter-rater reliability and concurrent validity with other measures. This tool is widely used in clinical trials concerning psychopathology treatments and has good sensitivity to clinical change.

Full Information

First Posted
January 27, 2022
Last Updated
February 6, 2022
Sponsor
Tel Aviv University
search

1. Study Identification

Unique Protocol Identification Number
NCT05243459
Brief Title
Testing the Efficacy of an Eye-tracking-based Treatment in Reducing Stress-related Symptoms in Veterans With PTSD
Official Title
Testing the Efficacy of an Eye-tracking-based Treatment in Reducing Stress-related Symptoms in Veterans With PTSD
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2021 (Actual)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tel Aviv University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will examine the efficacy of a feedback-based treatment applying eye-tracking (Gaze-Contingent Music Reward Therapy) to change attention and gaze patterns associated with angry faces relative to a response-time-based attention bias modification treatment applying the dot-probe task and a control group.
Detailed Description
The study will recruit veterans with posttraumatic stress disorder (PTSD) due to a trauma acquired during military service. A compatibility check and initial filtering will happen via phone call, using basic symptom questionnaires for self-report and initial examination of exclusion criteria. This study has four phases: Clinical Assessment - Participants who pass the initial filtering and express a desire to participate in the study will be invited to a structured clinical interview during which clinical and practical inclusion and exclusion criteria will be examined by an independent evaluator (a clinical psychologist). After an explanation about the study and provision of signed informed consent from the participant, the clinical interview (CAPS-5 and MINI) will be conducted and self-report questionnaires will be completed: Post-trauma Checklist (PCL) - PTSD symptoms Patient Health Questionnaire (PHQ) - Depression Symptoms Attention Bias Questionnaire (ABQ) - Attention Patterns Attention Control Scale (ACS) - Attention Control Attention bias measurement - participants will perform computerized tasks aimed to measure their attention bias prior to treatment. Free viewing of 30 matrices each with 16 faces (8 with neutral facial expression and 8 with angry facial expression) while monitoring gaze location with passive eye-tracking technology - duration of this assessment is about 15 minutes. Attention bias measurement using a dot-probe task in which two faces are presented on the screen and replaced by an arrow pointing right or left, and the participant has to indicate the arrow's direction by pressing a key - duration of the task is about 5 minutes. Generic Flanker attention task, in which a middle arrow is presented with additional arrows to the right and left (for example <<><< or >>>>>) and the participant is asked to identify the direction of the middle arrow by pressing a key - duration of the task is about 5 minutes. Attention Training - Next participants will be randomly assigned to one of three groups. 8 sessions of Gaze Contingent Music Reward Therapy (GC-MRT) - In every session, the participant chooses music to which to listen and is then asked to view matrices of 16 faces as described above. The music plays when the participant views neutral faces and stops when viewing angry faces - each meeting lasts about 20 minutes. 8 sessions of Attention Bias Modification Treatment based on a dot-probe task described above with one difference: While in the assessment task the probe location is counterbalanced at neutral and angry faces locations, in the treatment task the arrow always appears at the neutral face location - each session takes about 20 minutes. Control group in which participants are exposed to the same procedure as GC-MRT but the music will play continually without contingency to participant's gaze. Post-Training Assessment and Measurements - After the 8 treatment sessions, participants will undergo another clinical interview and the same questionnaires and attention assessment tasks similar to those conducted before the treatment. The clinical interview, questionnaires, and attention measurements will occur again after three months from the end of treatment (follow-up).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Posttraumatic Stress Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Gaze-Contingent Feedback Training
Arm Type
Experimental
Arm Description
In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the veteran will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracking technology, the veteran will be instructed to view the matrices of faces as he chooses, as described above in the assessment task. The music chosen by the veteran will play only when s/he is looking at neutral faces and it will stop when s/he looks at threatening faces.
Arm Title
RT-Based Attention Bias Modification
Arm Type
Active Comparator
Arm Description
The task consists of 160 trials. Each trial begins with a centrally-presented fixation cross (+), on which the participant is asked to focus for 500ms. When it disappears, two stimuli will be presented 1.5cm above and below the previous fixation cross for 500ms. After the stimuli disappear, a target probe (right- or left-pointing arrowhead) will appear in place of one of the stimuli, and the participant will be asked to indicate which target probe is presented by pressing the respective key. The target probe will remain on the screen until the participant's response, after which a new trial will begin. Participants are instructed to identify the probe type as quickly and accurately as possible. In the training task, all of the target probes will appear in the neutral face location. Thus, over multiple trials, learning occurs that the threatening face predicts the location of the target probe, thereby achieving the desiring change in attention patterns.
Arm Title
Non-Contingent Feedback Training
Arm Type
Placebo Comparator
Arm Description
This condition is based on the aforementioned eye-tracking task with a fundamental change - The music chosen by the veteran will play continuously without any reinforcement for looking at threat or neutral faces.
Intervention Type
Behavioral
Intervention Name(s)
Gaze-Contingent Feedback Training
Intervention Description
Feedback according to participants' viewing patterns, in order to modify their attention away from threat face stimuli.
Intervention Type
Behavioral
Intervention Name(s)
Attention Bias Modification
Intervention Description
Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
Intervention Type
Behavioral
Intervention Name(s)
Non-Contingent Feedback Training
Intervention Description
Participants listen to a musical track they chose while viewing the face matrices. The music is played throughout and is not contingent upon gaze behavior.
Primary Outcome Measure Information:
Title
Change in Clinician-rated PTSD symptoms from Pre- to Post-Treatment
Description
Change in total score on the Clinician Administered PTSD Scale (CAPS-5) from pre- to post-treatment
Time Frame
1.5-2 months
Title
Clinician-rated PTSD symptoms at 3-month Follow-up
Description
Total score on the Clinician Administered PTSD Scale (CAPS-5) at 3-month Follow-up
Time Frame
3 Months after treatment completion
Title
Change in PTSD Diagnosis from Pre- to Post-Treatment
Description
Change in PTSD diagnosis, derived from CAPS-5 corresponding to DSM-5 criteria, from pre- to post-treatment
Time Frame
1.5-2 months
Title
PTSD Diagnosis at 3-month Follow-up
Description
PTSD diagnosis derived from CAPS-5 corresponding to DSM-5 criteria at 3-month Follow-up
Time Frame
3 Months after treatment completion
Secondary Outcome Measure Information:
Title
Change in Patient-rated PTSD symptoms from Pre- to Post-Treatment
Description
Change in score on self-report questionnaire Posttraumatic stress disorder checklist for DSM-5 (PCL-5) from Pre- to Post-Treatment. The total score, ranging from 0 to 80, reflects PTSD symptom severity, with higher scores representing greater severity.
Time Frame
1.5-2 months
Title
Patient-rated PTSD symptoms at 3-month Follow-up
Description
Score on self-report questionnaire Posttraumatic stress disorder checklist for DSM-5 (PCL-5) at 3-month Follow-up. The total score, ranging from 0 to 80, reflects PTSD symptom severity, with higher scores representing greater severity.
Time Frame
3 Months after treatment completion
Title
Change in Patient-rated Depression symptoms from Pre- to Post-Treatment
Description
Change in Score on self-report Patient Health Questionnaire 9 (PHQ-9) from Pre- to Post-Treatment. The total score, ranging from 0-27, reflects severity of depressive symptoms, with higher scores representing greater severity.
Time Frame
1.5-2 months
Title
Patient-rated Depression symptoms at 3-month Follow-up
Description
Score on self-report Patient Health Questionnaire 9 (PHQ-9) at 3-month Follow-up. The total score, ranging from 0-27, reflects severity of depressive symptoms, with higher scores representing greater severity.
Time Frame
3 Months after treatment completion
Title
Pre-treatment Clinical Global Impression Scale
Description
Clinician Rated Symptom Severity & Improvement. Severity and improvement scales (CGI-S/I) will be used to assess participants global clinical condition. The CGI-S and the CGI-I are single-items, clinician-reported, measure assessing severity and improvement of illness using a 7-point Likert-type scale. The CGI-S/I has good inter-rater reliability and concurrent validity with other measures. This tool is widely used in clinical trials concerning psychopathology treatments and has good sensitivity to clinical change.
Time Frame
Up to 2 weeks pre-treatment
Title
Post-treatment Clinical Global Impression Scale
Description
Clinician Rated Symptom Severity & Improvement. Severity and improvement scales (CGI-S/I) will be used to assess participants global clinical condition. The CGI-S and the CGI-I are single-items, clinician-reported, measure assessing severity and improvement of illness using a 7-point Likert-type scale. The CGI-S/I has good inter-rater reliability and concurrent validity with other measures. This tool is widely used in clinical trials concerning psychopathology treatments and has good sensitivity to clinical change.
Time Frame
1-2 weeks post-treatment
Other Pre-specified Outcome Measures:
Title
Change in behavioral Attention Bias from Baseline to Post-treatment
Description
Change in Attention Bias will be assessed with two scores, one resulting from a response-time based dotprobe task and another from an eye-tracking computer task.
Time Frame
1.5-2 months
Title
Behavioral Attention Bias at 3-month Follow-up
Description
Attention Bias will be assessed again at the 3 month follow-up. It will be measured with two tasks, one response-time based dotprobe task and an eye-tracking computer task.
Time Frame
3 Months after treatment completion
Title
Change in behavioral Attention Control from Baseline to Post-treatment
Description
Change in Behavioral Attention Control from Baseline to Post-training Measurement will be assessed using a Flanker computer task.
Time Frame
1.5-2 months
Title
Behavioral Attention Control at 3-month Follow-up
Description
Behavioral Attention Control will be assessed again at 3-month Follow-up using a Flanker computer task.
Time Frame
3 Months after treatment completion
Title
Change in Subjective Attention Bias from Baseline to Post-treatment
Description
Change in score on self-report Attention Bias Questionnaire (ABQ) from Baseline to Post-treatment. The total score, ranging from 0 to 36, represents threat-related attention bias, with higher scores representing greater bias toward threat.
Time Frame
1.5-2 months
Title
Subjective Attention Bias at 3-month Follow-up
Description
Score on subjective Attention Bias Questionnaire (ABQ) at 3-month Follow-up. The total score, ranging from 0 to 36, represents threat-related attention bias, with higher scores representing greater bias toward threat.
Time Frame
3 Months after treatment completion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of PTSD according to the DSM-5 and related to military service, ages 20-70 Exclusion Criteria: Psychotic or Bipolar disorder, drug and alcohol abuse, high risk of harming self or others, other psychological treatment, vision problems that are not overcome with regular glasses, physical disability that prevents ability to operate computer.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yair Bar-Haim, PhD
Phone
+972-3-6405465
Email
yair1@post.tau.ac.il
First Name & Middle Initial & Last Name or Official Title & Degree
Chelsea D Gober, MA
Phone
+972-3-6405465
Email
chelseagober@mail.tau.ac.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yair Bar-Haim, PhD
Organizational Affiliation
Tel Aviv University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tel Aviv University
City
Tel Aviv
ZIP/Postal Code
6997801
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chelsea Gober, MA
Phone
+972-3-6405465
Email
chelseagober@mail.tau.ac.il
First Name & Middle Initial & Last Name & Degree
Yair Bar-Haim, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28103714
Citation
Lazarov A, Pine DS, Bar-Haim Y. Gaze-Contingent Music Reward Therapy for Social Anxiety Disorder: A Randomized Controlled Trial. Am J Psychiatry. 2017 Jul 1;174(7):649-656. doi: 10.1176/appi.ajp.2016.16080894. Epub 2017 Jan 20.
Results Reference
background

Learn more about this trial

Testing the Efficacy of an Eye-tracking-based Treatment in Reducing Stress-related Symptoms in Veterans With PTSD

We'll reach out to this number within 24 hrs